PDA Technical Report No. 41: Virus filtration

PDA Journal of Pharmaceutical Science and Technology

Volumn 59, Issue SUPPL. 2, 2005, Pages 1-42

  Sofer, Gail ^a   Brorson, Kurt ^b   Abujoub, Amin ^c   Aranha, Hazel ^d   Burnouf, Thierry ^e   Carter, Jeffrey ^f   Jocham, Uwe E ^g   Jornitz, Maik ^h   Korneyeva, Marina ⁱ   Krishnan, Mani ^f   Marcus Sekura, Carol ^d   Martin, Jerold ^j   Morgan, Michael ^d   Prashad, Mahesh ^h   Robertson, George A ^d   Rubino, Mike ^k   Shanks, Michael ^l   Shepherd, Ailsa ^d   Smith, Thomas ^m   Sundaram, Srikanth ⁿ   Van Engelenburg, Frank ^d   Willkommen, Hannelore ^d   Wojciechowski, Peter ^o   Yoshinari, K B ^d   more..

^a GE HEALTHCARE   (United Kingdom)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c BIOGEN   (United States)

^d Wyeth ^*

^e Human Plasma Product Services   (France)

^f MILLIPORE CORPORATION   (United States)

^g ZLB Bioplasma AG   (Switzerland)

^h SARTORIUS STEDIM BIOTECH GMBH   (Germany)

ⁱ BAYER CORPORATION   (United States)

^j Pall Life Science Biopharmaceuticals

^k ELI LILLY AND COMPANY   (United States)

^l Wellstat Biologics Corp   (United States)

^m GLAXOSMITHKLINE   (United Kingdom)

ⁿ Schering Plough Corporation   (Germany)

^o CENTOCOR INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGE; BIOTECHNOLOGY; DILUTION; FILTRATION; INSTRUMENT STERILIZATION; PARTICULATE MATTER; POROSITY; REVIEW;

EID: 27144447072     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Schosser, R.; Keller-Stanislawski, B.; Micha Nubling, C.; Lower, J. Causality assessment of suspected virus transmission by human plasma products. Transfusion 2001, 41, 1020-1029.
2. Farragua A. Evolving perspectives in product safety for haemophilia. Haemophilia 2002, 8, 236-243.
3. Gürtler, L. Blood-borne viruses: Hepatitis A to G. Seminar in Thrombosis and Hemostasis 2002, 28 (Suppl 1), 31-36.
4. Kleiman, S. Research, monitoring, and policy issues related to emerging pathogens. Vox Sang 2002, 83, 351-354.
5. Umemura, T.; Yeo, A. E.; Sottini, A.; et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001, 33, 1303-1311.
6. Chang, Y.; Cesarman, E.; Pessin, M. S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266, 1865-1869.
7. Sy, M.-S.; Gambetti, P.; Wong, B.-S. Human prion diseases. Medical Clinics of North America 2002, 86, 551-571.
8. Saldanha, J.; Minor, P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br. J. Haematol. 1996, 93, 531-537.
9. Office of Biological Research and Review, U.S. Food and Drug Administration. Points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology. 1985.
10. CPMP Note for Guidance on Virus Validation Studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95.
11. Levy, R. V.; Phillips, M. W; Lutz, H. Filtration and the Removal of Viruses from Biopharmaceuticals. In Filtration in the Biopharmaceutical Industry; Meltzer, T.; Jornitz, M., Eds.; Marcel Dekker, Inc.: New York, 1998; pp 619-646.
12. Burnouf-Radosevich, M.; Appourchaux, P.; Huart, J. J.; Burnoff, T. Nanofiltration, a new specific virus elimination method applied to high purity factor IX and factor XI concentrates. Vox Sang 1994, 67, 132-138.
13. Hoffer, L.; Schwinn, H.; Biesert, L.; Josic, D. Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration. J. Chromatogr., B. 1995, 669, 187-196.
14. Manabe, S. Removal of virus through novel membrane filtration method. Dev. Biol. Stand. 1996, 88, 81-90.
15. Aranha, H. Viral clearance strategies for biopharmaceutical safety. Part 1: General considerations. BioPharm 2001, 14 (1), 28-35.
16. Aranha, H. Viral clearance strategies for biopharmaceutical safety. Part 2: Filtration for viral clearance. BioPharm 2001, 14 (2), 32-43.
17. Aranha, H.; Forbes, S. Viral clearance strategies for biopharmaceutical safety. Part 3: A multifaceted approach to process validation. Pharm. Tech. 2001, June, 26-41.
18. Troccoli, N.; McIver, J.; Losikoff, A.; Poiley, J. Removal of viruses from humans intravenous immune globulin by 35 nm nanofiltration. Biologicals 1998, 26, 321-329.
19. O'Grady, J.; Losikoff, A.; Poiley, J.; Fickett, D.; Oliver, C. Virus removal studies using nanofiltration membranes, in: Viral safety and evaluation of viral clearance from biopharmaceutical products. Dev. Biol Stand. Brown F and AS. Lubiniecki, Eds. Karger: Basel, Switzerland, 1996, 319-326.
20. DiLeo, A. J.; Vacante, D. A.; Dean, E. F. Size exclusion removal of model mammalian viruses using a unique membrane system. Part I: Membrane qualification, Biologicals, 1993, 21, 275-286;
21. and DiLeo, A. J.; Vacante, D.; Deane, E. Size exclusion removal of model mammalian viruses using a unique membrane system. Part II: module qualification and process simulation. Biologicals 1993, 27, 287-296.
22. Grant, D. C. M.S. Thesis, University of Minnesota, Minneapolis, MN, 1988;
23. and Grant, D. C.; Liu, B. Y. H.; Fischer, W. G.; Bowling, R. A. Particle capture mechanisms in gases and liquids: an analysis of operative mechanisms. J. Environ. Sci. 1989, 42 (4), 43-51.
24. Hirasaki, T.; Noda, T.; Nakano, H.; Ishizaki, Y.; Manabe, S.; Yamamoto, N. Mechanism of removing Japanese encephalitis virus (JEV) and gold particles using cuprammonium regenerated cellulose hollow fiber (i-BMM or BMM) from aqueous solution containing protein. Polym. J. 1994, 26, 1244-1256.
25. Bolton, G., Cabatingan, M., Rubino, M., Lute, S., Brorson, K., and Bailey, M. Normal Flow Virus Filtration - Detection and Assessment of Endpoint in Bioprocessing. Biotechnol. Appl. Biochem., submitted.
26. Coetzee, J. N.; Lecatsas, G.; Coetzee, W. F.; Hedges, R. W. Properties of R plasmid R772 and the corresponding pilus-specific phage PR772. J. Gen. Microbiol. 1979, 110, 263-273.
27. Lute, S.; Aranha, H.; Tremblay, D.; Liang, D.; Ackermann, H.-W.; Chu, B.; Moineau, S.; Brorson, K. Characterization of coliphage PR772 and evaluation of its use for filter performance testing. Appl. Environ. Microbiol. 2004, 70, 4864-4869.
28. Pujar, N. S.; Zydney, A. L. Electrostatic effects on protein partitioning in size exclusion chromatography and membrane ultrafiltration. J. Chromatogr., A. 1991, 796 (2), 229-238.
29. Parenteral Drug Association. Sterilizing Filtration of Liquids; Technical Report #26, 1998. Available for order at www.pda.org.
30. Carter, J.; Lutz, H. Validation of virus filtration: Ensuring regulatory compliance. Bioprocess International 2003, 1, 52-62.
31. ICH Q5A. Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. 1997. Available at www.ifpma.org/ich5q. html.
32. International Committee on Taxonomy of Viruses. Virus Taxonomy, Classification and Nomenclature of Viruses, 7th Report of the International Committee on Taxonomy of Viruses; Van Regenmortel, M.; Fauquet, C.; Bishop, D.; Carstens, E.; Estes, M.; Lemon, S.; Maniloff, J.; Mayo, M.; McGeoch, D.; Pringle, C.; Wickner R., Eds.; Academic Press: San Diego, CA, 1998.
33. Korneyeva, M.; Charles, P.; Li, H.; McNaull, S.; Smith, S.; Petteway, S.; Pifat, D. Factors influencing virus removal and product yield during nanofiltration of highly purified plasma derived protein with thrombolytic activity. Int. J. Hematology 2002, 76 (Supplement 1), 29.
34. ICH Q2a Text on Analytical Validation Procedures (1994) and Q2b Validation of Analytical Procedures: Methodology (1996). Available at www.ich.org.
35. Brorson, K.; Sofer, G.; Robertson, G.; Lute, S.; Martin, J.; Aranha, H.; Haque, M.; Yoshinari, K.; Moroe, I.; Morgan, M.; Yamaguchi, F.; Carter, J.; Krishnan, M.; Etzel, M.; Riorden, W.; Korneyeva, M.; Rubino, M.; Sundaram, S.; Wilkommen, H.; Wojciechowski, P. Prototype demonstration of the large pore size virus filter test method recommended by the PDA virus filter task force. In preparation.